3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
2
Unknown
2
Completed
2
Suspended
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
6
Triple Negative Breast Neoplasms
4
Breast Neoplasms
4
Sarcoma
3
Stomach Neoplasms
2
Dendritic Cell Sarcoma, Interdigitating
2
Wilms Tumor
1
Thyroid Neoplasms
1
Thymoma
1
Thymic epithelial tumor
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Mediastinal Neoplasms
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia
1
Hodgkin Disease
1
Fallopian Tube Neoplasms
1
Enteropathy-Associated T-Cell Lymphoma
1
Endometrial Neoplasms
1
Carcinoma, Pancreatic Ductal
1
Carcinoma
1
Ann Arbor Stage II Mantle Cell Lymphoma
1
Advanced Gastric Cancer
1
Interventions
Vincristine
1
Prednisone
1
Doxorubicin
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Enteropathy-Associated T-Cell Lymphoma
×
Doxorubicin
×
Clear all
NCT06701344
2024-11-22
GOAL
Ruijin Hospital
Phase 2
Not yet recruiting
7 enrolled